trebananib

Known as: trenananib 
An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
05101520122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
LESSONS LEARNED Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular… (More)
  • figure 1
  • table 1
Is this relevant?
2016
2016
PURPOSE Trebananib, a peptibody that blocks binding of angiopoietin-1 and -2 to Tie2, significantly prolonged progression-free… (More)
Is this relevant?
2015
2015
PURPOSE Trebananib, an investigational recombinant peptide-Fc fusion protein, neutralizes the receptor-ligand interaction between… (More)
Is this relevant?
2015
2015
UNLABELLED The primary aim of this study was to assess the potential of in vivo photoacoustic tomography for direct functional… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
OBJECTIVE To examine the tolerability and antitumor activity of trebananib plus pegylated liposomal doxorubicin (PLD) or… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2014
2014
BACKGROUND Trebananib, an investigational peptibody, binds to angiopoietin 1 and 2, thereby blocking their interaction with Tie2… (More)
Is this relevant?
2013
2013
Background:This phase 2 study evaluated trebananib (AMG 386), an investigational peptide-Fc fusion protein that neutralises the… (More)
  • table 1
  • figure 1
  • table 2
  • table 4
  • figure 2
Is this relevant?
2013
2013
BACKGROUND We evaluated AMG 386, an investigational peptibody that neutralizes the interaction between angiopoietins-1 and -2 and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2012
2012
To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of trebananib (AMG 386)—a first-in-class… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?